



PRESS RELEASE

Published: 2016-08-25; 08:00:00 CEST

King's College London purchases PreciseInhale®

STOCKHOLM, SWEDEN – February 25, 2016. King's College Institute of Pharmaceutical Science is purchasing ISAB's PreciseInhale system to strengthen its capabilities in respiratory research.

ISAB CEO Fredrik Sjövall: "We're delighted to deepen our relationship with the outstanding team of innovators at King's. It helps us generate important publications, and gives King's the capability to generate a world-class standard of detailed, high-quality data."

Professor Ben Forbes, at King's Institute of Pharmaceutical Science: "ISAB are highly expert and take a collaborative academic approach. We have been collaborating with them on our simulated lung lining fluid project since 2014. Their bespoke engineered kit is excellent."

Precision dosing with two *in vivo* modules: The purchase includes PreciseInhale's nose-only *in vivo* module which exposes rodents to aerosols one at a time, and delivers real inhalation dosing with a typical SD of around 10 percent. The intratracheal inhalation module, unique to ISAB, allows high control and precision dosing, the distribution pattern of administered materials in the lungs it provides more closely resembles that obtained during clinical inhalation exposures.

PreciseInhale will be installed at King's in the first half of April 2016. ISAB CEO Fredrik Sjövall: "It speaks volumes about the quality of our system and the data it generates that PreciseInhale has been chosen to play such a key role in King's pioneering work – work that will potentially power faster, more cost-effective testing of drugs in a world with fast-growing cases of COPD and asthma."

1

About King's College London

King's College London is one of the world's leading Universities for both education and research, with disciplines connecting across different cultures, subjects, institutions and geographies. King's is dedicated to the advancement of knowledge, learning and understanding in the service of global society. Through strong partnerships and research and teaching excellence, King's is recognised as a thought-leader on interdisciplinary themes of global significance. Visit <http://www.kcl.ac.uk/index.aspx>

About Inhalation Sciences AB

Inhalation Sciences AB's aerosol R&D platform PreciseInhale delivers high-resolution lung absorption and retention data with a standard deviation of, typically, <10% PreciseInhale help's inhaled drug developers reduce their attrition rates, enhance their performance evaluation and ultimately get nearer to IVIVC. ISAB carries out Contract Research work with novel and generic inhalation drug developers, toxicology and environmental research institutes and university research institutes worldwide. Visit inhalation.se

For further information, please contact:

Fredrik Sjövall, CEO

fredrik.sjovall@inhalation.se

+46 (0)70 64 508 75

Per Gerde, CSO

per.gerde@inhalation.se

+46 (0)72 21 984 49